<p>(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox.

GUEST:
Shire CEO Flemming Ornskov on the outlook for the company after getting FDA approval for Xiidra drops to treat dry-eye disease.</p><p>See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.</p>

Pemberton's Durcikova: Investing in Toronto Real Estate (Audio)

Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company and industry research. Watch us LIVE on YouTube: http://bit.ly/3vTiACF.

Podtrac